| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | Envoy Medical, Inc.: Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant | 223 | Newsfile |
White Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced... ► Artikel lesen | |
| 27.03. | Envoy Medical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ENVOY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 23.03. | Envoy Medical GAAP EPS of -$1.23, revenue of $0.02M | 1 | Seeking Alpha | ||
| 23.03. | Envoy Medical, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 23.03. | Envoy Medical, Inc.: Envoy Medical Reports Full Year 2025 Financial Results | 596 | Newsfile | Received FDA approval to expand fully implanted Acclaim Cochlear Implant Pivotal Clinical Trial to final stageStrengthened balance sheet by extinguishing $32 million in debtSubsequent to year-end... ► Artikel lesen | |
| 11.03. | Envoy Medical, Inc.: Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant | 320 | Newsfile | White Bear Lake, Minnesota--(Newsfile Corp. - March 11, 2026) - Envoy Medical Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing... ► Artikel lesen | |
| 11.03. | EXCLUSIVE: Envoy Medical Hits Trial Milestone For Cochlear Implant Designed To Work With Natural Ear | 2 | Benzinga.com | ||
| 27.02. | Envoy Medical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.02. | Envoy Medical regains compliance with Nasdaq | 5 | Seeking Alpha | ||
| 24.02. | Envoy Medical: Nasdaq-Konformität nach Bilanzstärkung wiederhergestellt | 6 | Investing.com Deutsch | ||
| 24.02. | Envoy Medical, Inc.: Envoy Medical Regains Compliance with Nasdaq Listing Requirement | 324 | Newsfile | White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing... ► Artikel lesen | |
| 23.02. | Envoy Medical receives three new patents for cochlear implant tech | 4 | Investing.com | ||
| 23.02. | Envoy Medical, Inc.: Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space | 325 | Newsfile | White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing... ► Artikel lesen | |
| 19.02. | Envoy Medical raises $30 million, nears completion of cochlear implant trial | 2 | Investing.com | ||
| 19.02. | Envoy Medical sichert sich 30 Mio. US-Dollar und treibt klinische Studie für Cochlea-Implantat voran | 2 | Investing.com Deutsch | ||
| 19.02. | Envoy Medical, Inc.: Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial | 235 | Newsfile | Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor Closing of $30 million in gross proceeds in upsized... ► Artikel lesen | |
| 17.02. | Envoy Medical, Inc.: Envoy Medical Nears Completion of Enrollment in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant | 228 | Newsfile | White Bear Lake, Minnesota--(Newsfile Corp. - February 17, 2026) - Envoy Medical Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing... ► Artikel lesen | |
| 12.02. | Envoy Medical, Inc.: Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering | 367 | Newsfile | $30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cashOffering led by Nantahala Capital... ► Artikel lesen | |
| 11.02. | Envoy Medical, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.02. | Envoy Medical announces pricing of up to $78M public offering | 3 | Seeking Alpha |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 44,700 | +0,45 % | EQS-News: Fresenius SE & Co. KGaA: FutureFresenius zahlt sich aus: S&P Global Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Rating
FutureFresenius zahlt sich aus: S&P Global Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an
08.04.2026... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 37,770 | +1,15 % | GOLDMAN SACHS stuft Siemens Healthineers auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Siemens Healthineers von 52 auf 45 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Vor der Berichtssaison... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,340 | +0,75 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 25,940 | +1,65 % | GOLDMAN SACHS stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Carl Zeiss Meditec von 36 auf 31 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Die Aktien der Jenaer... ► Artikel lesen | |
| GERRESHEIMER | 17,070 | +0,41 % | Aktien Frankfurt: Dax legt zu - vage Hoffnung auf Ende des Ukraine-Kriegs | FRANKFURT (dpa-AFX) - Sehr vage Hoffnungen auf ein Ende des Kriegs in der Ukraine haben am Freitag die Kurse am deutschen Aktienmarkt angeschoben. Am frühen Nachmittag legte der Dax um 0,8 Prozent... ► Artikel lesen | |
| PROGYNY | 16,300 | -1,39 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| BILLIONTOONE | 81,13 | -1,65 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| DRAEGERWERK | 94,50 | +0,75 % | Draegerwerk AG & Co. KGaA: Online-Präsentation für Investoren als Teil der German Select 7 Conference am 14.04.2026 | Vor diesem Hintergrund veranstaltet mwb research am 14.04.2026 um 14:00 CEST einen Online-Roundtable mit Thomas Fischler (Head of Treasury & Investor Relations). Nach einer Präsentation besteht die... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,510 | -4,07 % | Alignment Healthcare (ALHC) Soars 16% on Medicare Reimbursement Hike | ||
| BRIGHTSPRING HEALTH SERVICES | 45,330 | -1,33 % | BrightSpring Health Services, Inc. to Announce First Quarter 2026 Financial Results on May 1, 2026 | ||
| ECKERT & ZIEGLER | 14,620 | +1,74 % | Eckert & Ziegler erhält MDR-Zertifizierung für Augentumorbehandlung | Die Eckert & Ziegler BEBIG GmbH, eine auf Brachytherapie spezialisierte Tochtergesellschaft der Eckert & Ziegler SE, hat die MDR-Zertifizierung der EU für ihre Ruthenium-106-Augenapplikatoren erhalten.... ► Artikel lesen | |
| HEARTFLOW | 26,980 | -0,37 % | Stifel reiterates Heartflow stock rating on clinical data strength | ||
| TALKSPACE | 5,170 | +0,10 % | Universal Health Services, Inc. to Acquire Talkspace, Inc. | Industry-leading virtual behavioral healthcare platform accelerates outpatient strategy with expanded access to care KING OF PRUSSIA, Pa. and NEW YORK, March 9, 2026 /PRNewswire/ -- Universal... ► Artikel lesen | |
| BETA BIONICS | 8,880 | -7,79 % | Beta Bionics, Inc.: Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 | IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| OTTOBOCK | 55,00 | +3,77 % | DEUTSCHE BANK RESEARCH stuft Ottobock auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Ottobock mit einem Kursziel von 81 Euro auf "Buy" belassen. Falko Friedrichs rechnet beim Prothesenhersteller mit einem schwächeren... ► Artikel lesen |